Apellis Pharmaceuticals Inc. (APLS) stock soared 9.62% in the pre-market session on Friday, following the release of its fourth-quarter 2024 earnings report.
The biopharmaceutical company reported a net loss of $36.35 million or $0.29 per share for the quarter. However, the losses were offset by strong product revenue of $191.17 million, reflecting robust sales growth for the company's products.
Despite the net loss, investors reacted positively to the revenue growth, driving the stock higher in anticipation of continued momentum. Operating expenses remained high at $238.69 million, but the market seems to be focused on the top-line performance for now.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。